It’s beginning to look a lot like . . .

Dr. Robert Malone, inventor of mRNA vaccines, warns parents not to let anyone give these toxic, unnecessary, useless “jabs” to their children — they can cause permanent heart disease and other serious ailments; they DON’T provide immunity, and children areen’t at any serious risk from “COVID,” anyway:

So, of course, the good doctor is banned from Twatter. Why? Foul language? Of course not. Because he’s saying it’s all right for adults to cornhole small, defenseless children? Of course not. (Though in fact, that might be OK on today’s Twatter.)

No, the totally fictitious “community standard” being violated here is the open, responsible discussion of the harm/benefit anlaysis of the experimental injections being promoted by the evil Davos gang, who acknowledge they want to reduce the world’s human population, and the demons at the CDC/NIH, who profit enormously from these so-called “vaccines” (before AND after they move through the “revolving door” into Big Pharma), who fund virus weaponization research in genocidal Red China, and who are reponsible for hundreds of thousands of deaths “by Remdesivir-and-Ventilator” that could have been prevented by early treatment with cheap Ivermectin and Hydroxychloroquine — which they’ve tried to ban!

You know — the kind of energentic and open debate and peer-review that used to be called “science”:

Dr. Robert Malone on Mass Formation Psychosis:

OR SEE: . . .

Dr. Malone discusses absence of informed consent and the silencing of vaccine queries:

2 Comments to “It’s beginning to look a lot like . . .”

  1. Steve Briggs Says:
    New patent-free COVID vaccine developed as “gift to the world”
    By Rich Haridy

    January 03, 2022

    The initial Corbevax vaccine research was led by Maria Elena Bottazzi and Peter Hotez from the Texas Children’s Hospital Center for Vaccine Development

    Texas Children’s Hospital


    A new COVID-19 vaccine, developed by researchers from the Texas Children’s Hospital and Baylor College of Medicine, is being offered patent-free to vaccine manufacturers across the world. Human trials have shown the vaccine to be safe and effective, with India already authorizing its use as production ramps up to over 100 million doses per month.

    The vaccine has been named Corbevax and it is based on a traditional protein-based technology that has been safely used for decades. Like other COVID-19 vaccines, Corbevax focuses on the coronavirus spike protein, but instead of using mRNA to direct our cells to produce those spike proteins internally it delivers lab-grown spike proteins to the body.

    The researchers took the gene that codes for the spike protein and engineered yeast to produce it. These proteins are collected, purified, and combined with an adjuvant to enhance immune responses. This exact method has been used to produce the hepatitis B vaccine for years.

    “Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world,” says Maria Elena Bottazzi, one of the lead researchers on the project.

    In late 2020 the US research team developing the vaccine joined forces with India-based pharma company Biological E to begin clinical trials and establish manufacturing capacity. Across 2021 those clinical trials included several thousand participants and ultimately found Corbevax to be safe and effective at generating robust immune responses to SARS-CoV-2.

    The trial data was compared to an already approved vaccine called Covishield (the Indian-made version of Astrazeneca’s well-known COVID-19 vaccine). Corbevax generated significantly fewer adverse effects than Covishield and produced superior immune responses.

    Neutralizing antibody responses to Corbevax indicate the vaccine should be at least 80 percent effective at preventing symptomatic COVID-19 from the Delta variant. Specific data against the Omicron variant is expected soon but it is hypothesized to be at least as effective as most currently available vaccines.

    Perhaps the most important feature of this new vaccine is the fact it has been developed as a patent-free product that can be easily manufactured by vaccine-producers around the world. Peter Hotez, one of the researchers leading the project, has described it as a “gift to the world,” pointing out the technology has already been transferred to vaccine producers in India, Indonesia, Bangladesh and Botswana.

    “This announcement is an important first step in vaccinating the world and halting the pandemic,” says Hotez. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant.”

    The vaccine is similar to Novavax’s protein sub-unit COVID-19 vaccine, which was recently authorized for emergency use in a number of countries around the world. India is the first country to issue emergency authorization to Corbevax and Biological E reportedly has 150 million doses ready to go, with production capacity set for 100 million doses per month from February.

  2. kingsnake Says:

    1) The Science!
    2) Scientist disagrees.
    3) Cancel scientist.
    4) All scientists agree.
    5) Profit!